Global Gene Therapy Viral Vector and Plasmid DNA Market Growth 2025-2031
Description
The global Gene Therapy Viral Vector and Plasmid DNA market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Viral vector and plasmid DNA are tools to transfer genetic material into cells. Viral vectors are generally utilized as vectors for gene therapy. There are various types of vectors, such as lentivirus, adenovirus, adeno-associated virus (AAV), and others, which include herpes simplex virus and chimeric viral vectors.
United States market for Gene Therapy Viral Vector and Plasmid DNA is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Gene Therapy Viral Vector and Plasmid DNA is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Gene Therapy Viral Vector and Plasmid DNA is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Gene Therapy Viral Vector and Plasmid DNA players cover Lonza, Merck KGaA, Thermo Fisher Scientific, Charles River Laboratories, Catalent, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Gene Therapy Viral Vector and Plasmid DNA Industry Forecast” looks at past sales and reviews total world Gene Therapy Viral Vector and Plasmid DNA sales in 2024, providing a comprehensive analysis by region and market sector of projected Gene Therapy Viral Vector and Plasmid DNA sales for 2025 through 2031. With Gene Therapy Viral Vector and Plasmid DNA sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Therapy Viral Vector and Plasmid DNA industry.
This Insight Report provides a comprehensive analysis of the global Gene Therapy Viral Vector and Plasmid DNA landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gene Therapy Viral Vector and Plasmid DNA portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Therapy Viral Vector and Plasmid DNA market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy Viral Vector and Plasmid DNA and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy Viral Vector and Plasmid DNA.
This report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy Viral Vector and Plasmid DNA market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Viral Vectors
Plasmid DNA
Segmentation by Application:
Cell and Gene Therapy
Vaccine Development
Research
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Lonza
Merck KGaA
Thermo Fisher Scientific
Charles River Laboratories
Catalent
WuXi AppTec
FUJIFILM
GenScript Biotech
Takara Bio
Oxford Biomedica
Novartis
Precision Biosciences
Bluebird Bio
Sartorius AG
Danaher
SIRON Biotech
VGXI
Waisman Biomanufacturing
Kaneka Eurogentec
PlasmidFactory
ATUM
Addgene
Cell and Gene Therapy Catapult
Batavia biosciences
Altogen Biosystems
Key Questions Addressed in this Report
What is the 10-year outlook for the global Gene Therapy Viral Vector and Plasmid DNA market?
What factors are driving Gene Therapy Viral Vector and Plasmid DNA market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Gene Therapy Viral Vector and Plasmid DNA market opportunities vary by end market size?
How does Gene Therapy Viral Vector and Plasmid DNA break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Viral vector and plasmid DNA are tools to transfer genetic material into cells. Viral vectors are generally utilized as vectors for gene therapy. There are various types of vectors, such as lentivirus, adenovirus, adeno-associated virus (AAV), and others, which include herpes simplex virus and chimeric viral vectors.
United States market for Gene Therapy Viral Vector and Plasmid DNA is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Gene Therapy Viral Vector and Plasmid DNA is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Gene Therapy Viral Vector and Plasmid DNA is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Gene Therapy Viral Vector and Plasmid DNA players cover Lonza, Merck KGaA, Thermo Fisher Scientific, Charles River Laboratories, Catalent, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Gene Therapy Viral Vector and Plasmid DNA Industry Forecast” looks at past sales and reviews total world Gene Therapy Viral Vector and Plasmid DNA sales in 2024, providing a comprehensive analysis by region and market sector of projected Gene Therapy Viral Vector and Plasmid DNA sales for 2025 through 2031. With Gene Therapy Viral Vector and Plasmid DNA sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Therapy Viral Vector and Plasmid DNA industry.
This Insight Report provides a comprehensive analysis of the global Gene Therapy Viral Vector and Plasmid DNA landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gene Therapy Viral Vector and Plasmid DNA portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Therapy Viral Vector and Plasmid DNA market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy Viral Vector and Plasmid DNA and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy Viral Vector and Plasmid DNA.
This report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy Viral Vector and Plasmid DNA market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Viral Vectors
Plasmid DNA
Segmentation by Application:
Cell and Gene Therapy
Vaccine Development
Research
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Lonza
Merck KGaA
Thermo Fisher Scientific
Charles River Laboratories
Catalent
WuXi AppTec
FUJIFILM
GenScript Biotech
Takara Bio
Oxford Biomedica
Novartis
Precision Biosciences
Bluebird Bio
Sartorius AG
Danaher
SIRON Biotech
VGXI
Waisman Biomanufacturing
Kaneka Eurogentec
PlasmidFactory
ATUM
Addgene
Cell and Gene Therapy Catapult
Batavia biosciences
Altogen Biosystems
Key Questions Addressed in this Report
What is the 10-year outlook for the global Gene Therapy Viral Vector and Plasmid DNA market?
What factors are driving Gene Therapy Viral Vector and Plasmid DNA market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Gene Therapy Viral Vector and Plasmid DNA market opportunities vary by end market size?
How does Gene Therapy Viral Vector and Plasmid DNA break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
162 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Gene Therapy Viral Vector and Plasmid DNA by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Gene Therapy Viral Vector and Plasmid DNA by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
